 Home > Active Ingredient News > Drugs Articles > The scope of procurement with volume continues to expand, how should multinational pharmaceutical companies respond?

The scope of procurement with volume continues to expand, how should multinational pharmaceutical companies respond?

 Last Update: 2022-08-15
 Source: Internet
 Author: User

Tags

step 22

study model

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In January 2022, the executive meeting of the State Council decided to normalize and institutionalize the centralized procurement of drugs and high-value medical consumabl.

In fact, whether it is winning the bid or rejecting the bid, centralized procurement is bad for multinational pharmaceutical compani.

Strategic contraction to focus on main business

According to the review of public information, in the fifth round of procurement with volume, AstraZeneca has a total of 8 products shortlisted, and it is one of the multinational pharmaceutical companies with the largest number of shortlisted products in the fifth round of procureme.

▲ Source: GBIHealth, Minet, Medicine Cube

In the face of major market changes, AstraZeneca is strategically shrinking and adjusting old business.

Accelerate the research and development and launch of major products, and hedge the losses caused by centralized procureme.

Digital strategy empowers the entire value chain of enterprises

Looking at the strategic plans of leading multinational pharmaceutical companies in recent years, digital transformation has become one of the crucial strategic measur.

Through the analysis of the digital strategies of many multinational pharmaceutical companies, the author can see that at present, the digital initiatives of leading multinational pharmaceutical companies are mainly reflected in three aspects: digitalization of research and development, digital medical innovation solutions throughout the patient journey (screening, diagnosis, treatment, continuous management), digital marketi.

R&D digitalization

How to quickly and accurately develop innovative drugs is the basis for the sustainable development of pharmaceutical compani.

Apply data science and artificial intelligence to build disease knowledge maps to discover effective targets or signaling pathways; expand multiple treatment modalities; establish AI technology platforms to assist molecular simulation and molecular synthesis; use predictive science to reduce the number of patients in clinical trials, earlier Predicting the success or failure of clinical trials and synthesizing innovative endpoints to improve clinical efficien.

Roche fuses real-world data and artificial intelligence to study pathogenesis and intervention characteristics, and to improve disease classification and disease progression predicti.

▲Source: Digital technology and advanced analytics in Roche, 2020

Innovative solutions for digital healthcare throughout the patient journey

For a long time, the hospital has played a leading role in the medical treatment channel, which undertakes all the needs of patients on the medical path from diagnosis and treatment to prescription and repurcha.

Taking Novartis as an example, the Chinese market is a must for Novart.

While making up for the pain points of the traditional chronic disease management model, it also helps Novartis to carry out patient education and user precipitation in a convenient w.

Digital Marketing

The traditional marketing methods of pharmaceutical companies rely on offline communication between pharmaceutical representatives and docto.

The digital marketing strategy of multinational pharmaceutical companies has changed from face-to-face static information-driven sales to providing accurate and personalized content to customers through digital channe.

▲Source: Digital technology and advanced analytics in Roche, 2020

Going a step further, Roche is trying to integrate customer data, patient data and market data, improve data transparency, and automatically analyze online data to form future predictions and insights, and provide marketing decision suggestio.

▲Source: Digital technology and advanced analytics in Roche, 2020

At this stage, procurement with volume has become a major policy in the pharmaceutical industry, and the strategic transformation of multinational pharmaceutical companies is an inevitable tre.

The measures and methods related to strategic transformation are still in the exploratory stage, and will continue to pay attention in the futu.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.